Logo image of AJ91.DE

DOCCHECK AG (AJ91.DE) Stock Fundamental Analysis

Europe - FRA:AJ91 - DE000A1A6WE6 - Common Stock

13 EUR
0 (0%)
Last: 10/3/2025, 7:00:00 PM
Fundamental Rating

6

AJ91 gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 11 industry peers in the Health Care Technology industry. While AJ91 has a great health rating, its profitability is only average at the moment. AJ91 has a correct valuation and a medium growth rate. Finally AJ91 also has an excellent dividend rating. These ratings would make AJ91 suitable for dividend investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

AJ91 had positive earnings in the past year.
AJ91 had a positive operating cash flow in the past year.
AJ91 had positive earnings in each of the past 5 years.
In the past 5 years AJ91 always reported a positive cash flow from operatings.
AJ91.DE Yearly Net Income VS EBIT VS OCF VS FCFAJ91.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M

1.2 Ratios

With a decent Return On Assets value of 9.09%, AJ91 is doing good in the industry, outperforming 63.64% of the companies in the same industry.
AJ91 has a Return On Equity of 13.18%. This is in the better half of the industry: AJ91 outperforms 63.64% of its industry peers.
The Return On Invested Capital of AJ91 (8.86%) is better than 63.64% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for AJ91 is in line with the industry average of 9.34%.
Industry RankSector Rank
ROA 9.09%
ROE 13.18%
ROIC 8.86%
ROA(3y)7.87%
ROA(5y)12.82%
ROE(3y)11.84%
ROE(5y)19.17%
ROIC(3y)9.31%
ROIC(5y)15.17%
AJ91.DE Yearly ROA, ROE, ROICAJ91.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

AJ91's Profit Margin of 9.82% is in line compared to the rest of the industry. AJ91 outperforms 54.55% of its industry peers.
AJ91's Profit Margin has been stable in the last couple of years.
Looking at the Operating Margin, with a value of 12.33%, AJ91 is in the better half of the industry, outperforming 63.64% of the companies in the same industry.
In the last couple of years the Operating Margin of AJ91 has declined.
AJ91's Gross Margin of 79.18% is fine compared to the rest of the industry. AJ91 outperforms 63.64% of its industry peers.
In the last couple of years the Gross Margin of AJ91 has remained more or less at the same level.
Industry RankSector Rank
OM 12.33%
PM (TTM) 9.82%
GM 79.18%
OM growth 3Y-13.6%
OM growth 5Y-2.73%
PM growth 3Y-9.54%
PM growth 5Y0.26%
GM growth 3Y11.03%
GM growth 5Y-0.26%
AJ91.DE Yearly Profit, Operating, Gross MarginsAJ91.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

9

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AJ91 is creating some value.
AJ91 has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for AJ91 has been increased compared to 5 years ago.
AJ91 has a better debt/assets ratio than last year.
AJ91.DE Yearly Shares OutstandingAJ91.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
AJ91.DE Yearly Total Debt VS Total AssetsAJ91.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

An Altman-Z score of 4.51 indicates that AJ91 is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 4.51, AJ91 belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
There is no outstanding debt for AJ91. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.51
ROIC/WACC1.27
WACC6.98%
AJ91.DE Yearly LT Debt VS Equity VS FCFAJ91.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M 40M

2.3 Liquidity

A Current Ratio of 2.74 indicates that AJ91 has no problem at all paying its short term obligations.
AJ91's Current ratio of 2.74 is amongst the best of the industry. AJ91 outperforms 90.91% of its industry peers.
A Quick Ratio of 2.50 indicates that AJ91 has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 2.50, AJ91 belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.74
Quick Ratio 2.5
AJ91.DE Yearly Current Assets VS Current LiabilitesAJ91.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 133.18% over the past year.
Measured over the past years, AJ91 shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.57% on average per year.
Looking at the last year, AJ91 shows a small growth in Revenue. The Revenue has grown by 0.69% in the last year.
AJ91 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.68% yearly.
EPS 1Y (TTM)133.18%
EPS 3Y-22.65%
EPS 5Y10.57%
EPS Q2Q%501.79%
Revenue 1Y (TTM)0.69%
Revenue growth 3Y-14.46%
Revenue growth 5Y10.68%
Sales Q2Q%7.91%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AJ91.DE Yearly Revenue VS EstimatesAJ91.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 12.50 indicates a correct valuation of AJ91.
Based on the Price/Earnings ratio, AJ91 is valued a bit cheaper than the industry average as 72.73% of the companies are valued more expensively.
AJ91's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.86.
Industry RankSector Rank
PE 12.5
Fwd PE N/A
AJ91.DE Price Earnings VS Forward Price EarningsAJ91.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, AJ91 is valued cheaply inside the industry as 90.91% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, AJ91 is valued cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 10.13
EV/EBITDA 4.28
AJ91.DE Per share dataAJ91.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

The decent profitability rating of AJ91 may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.18
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

8

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 5.77%, AJ91 is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 3.41, AJ91 pays a better dividend. On top of this AJ91 pays more dividend than 100.00% of the companies listed in the same industry.
AJ91's Dividend Yield is rather good when compared to the S&P500 average which is at 2.44.
Industry RankSector Rank
Dividend Yield 5.77%

5.2 History

The dividend of AJ91 has a limited annual growth rate of 4.52%.
Dividend Growth(5Y)4.52%
Div Incr Years1
Div Non Decr Years1
AJ91.DE Yearly Dividends per shareAJ91.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8

5.3 Sustainability

48.02% of the earnings are spent on dividend by AJ91. This is a bit on the high side, but may be sustainable.
The dividend of AJ91 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP48.02%
EPS Next 2YN/A
EPS Next 3YN/A
AJ91.DE Yearly Income VS Free CF VS DividendAJ91.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M 4M 6M 8M 10M
AJ91.DE Dividend Payout.AJ91.DE Dividend Payout, showing the Payout Ratio.AJ91.DE Dividend Payout.PayoutRetained Earnings

More info and screens

DOCCHECK AG

FRA:AJ91 (10/3/2025, 7:00:00 PM)

13

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)09-20 2024-09-20
Earnings (Next)N/A N/A
Inst Owners8.86%
Inst Owner ChangeN/A
Ins Owners71.92%
Ins Owner ChangeN/A
Market Cap65.91M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 5.77%
Yearly Dividend0.5
Dividend Growth(5Y)4.52%
DP48.02%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 12.5
Fwd PE N/A
P/S 1.23
P/FCF 10.13
P/OCF 8.63
P/B 1.64
P/tB 1.65
EV/EBITDA 4.28
EPS(TTM)1.04
EY8%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)1.28
FCFY9.87%
OCF(TTM)1.51
OCFY11.59%
SpS10.61
BVpS7.91
TBVpS7.87
PEG (NY)N/A
PEG (5Y)1.18
Profitability
Industry RankSector Rank
ROA 9.09%
ROE 13.18%
ROCE 14.96%
ROIC 8.86%
ROICexc 17.58%
ROICexgc 17.72%
OM 12.33%
PM (TTM) 9.82%
GM 79.18%
FCFM 12.1%
ROA(3y)7.87%
ROA(5y)12.82%
ROE(3y)11.84%
ROE(5y)19.17%
ROIC(3y)9.31%
ROIC(5y)15.17%
ROICexc(3y)16.17%
ROICexc(5y)32.75%
ROICexgc(3y)16.36%
ROICexgc(5y)34.31%
ROCE(3y)15.72%
ROCE(5y)25.61%
ROICexcg growth 3Y-26.82%
ROICexcg growth 5Y-2.82%
ROICexc growth 3Y-26.26%
ROICexc growth 5Y-1.57%
OM growth 3Y-13.6%
OM growth 5Y-2.73%
PM growth 3Y-9.54%
PM growth 5Y0.26%
GM growth 3Y11.03%
GM growth 5Y-0.26%
F-Score6
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 45.88%
Cap/Sales 2.11%
Interest Coverage 250
Cash Conversion 83.94%
Profit Quality 123.15%
Current Ratio 2.74
Quick Ratio 2.5
Altman-Z 4.51
F-Score6
WACC6.98%
ROIC/WACC1.27
Cap/Depr(3y)102.11%
Cap/Depr(5y)131.26%
Cap/Sales(3y)5.41%
Cap/Sales(5y)5.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)133.18%
EPS 3Y-22.65%
EPS 5Y10.57%
EPS Q2Q%501.79%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)0.69%
Revenue growth 3Y-14.46%
Revenue growth 5Y10.68%
Sales Q2Q%7.91%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y86.96%
EBIT growth 3Y-26.09%
EBIT growth 5Y7.66%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.74%
FCF growth 3Y-1.99%
FCF growth 5Y54.46%
OCF growth 1Y1.69%
OCF growth 3Y-11.25%
OCF growth 5Y33.53%